Find Paper, Faster
Example:10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2
Allergy  (IF13.146),  Pub Date : 2021-09-08, DOI: 10.1111/all.15080
Mona O. Mohsen, Ina Balke, Simon Zinkhan, Villija Zeltina, Xuelan Liu, Xinyue Chang, Pascal S. Krenger, Kevin Plattner, Zahra Gharailoo, Anne-Cathrine S. Vogt, Gilles Augusto, Marianne Zwicker, Salony Roongta, Dominik A. Rothen, Romano Josi, Joana J. da Costa, Jan M. Sobczak, Aleksandra Nonic, Lee-Anne Brand, Katja Nuss, Byron Martina, Daniel E. Speiser, Thomas Kündig, Gary T. Jennings, Senta M. Walton, Monique Vogel, Andris Zeltins, Martin F. Bachmann

SARS-CoV-2 caused one of the most devastating pandemics in the recent history of mankind. Due to various countermeasures, including lock-downs, wearing masks, and increased hygiene, the virus has been controlled in some parts of the world. More recently, the availability of vaccines, based on RNA or adenoviruses, has greatly added to our ability to keep the virus at bay; again, however, in some parts of the world only. While available vaccines are effective, it would be desirable to also have more classical vaccines at hand for the future. Key feature of vaccines for long-term control of SARS-CoV-2 would be inexpensive production at large scale, ability to make multiple booster injections, and long-term stability at 4℃.